Skip to main content
Clinical Trials/NCT03116932
NCT03116932UnknownNot Applicable

Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part A

Puerto Rico Community Network for Clinical Research on AIDS1 site in 1 country225 target enrollmentStarted: November 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
225
Locations
1
Primary Endpoint
PrEP knowledge using a PrEP knowledge and acceptability questionnaire.

Study Overview

Brief Summary

The target population for this project will be men-who-have-sex-with-men (MSM) at high risk of HIV acquisition

Detailed Description

225 high risk MSM will be interviewed to understand the knowledge and acceptability of pre-exposure prophylaxis (PrEP) in this population in Puerto Rico. A 187 item questionnaire will administered which will evaluate socio-demographic information, sexual conducts, PrEP knowledge and PrEP acceptability.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

PrEP knowledge using a PrEP knowledge and acceptability questionnaire.

Time Frame: One visit

Measure the level of education of the study subjects in the topic of PrEP using a questionnaire.

PrEP acceptability using a PrEP knowledge and acceptability questionnaire.

Time Frame: One visit

Measure the degree of acceptance of PrEP in the study subjects

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Puerto Rico Community Network for Clinical Research on AIDS
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Vivian Tamayo-Agrait, MD

Principal Investigator

Puerto Rico Community Network for Clinical Research on AIDS

Study Sites (1)

Loading locations...

Similar Trials

Evaluating the Feasibility and... | Clinical Trial